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Abstract
Influenza, a highly contagious respiratory tract infection, affects
millions of adults and children each year. Several high-risk
populations include children, the elderly, the immunocompromised,
and recently the obese.Given the dramatic rise in obesity over the past
few decades, this increased risk for influenza infection poses a serious
public health threat because nearly 500 million adults and children
worldwide are classified as obese. Obesity impairs the immune
response to influenza and influenza vaccination through alterations
of the cellular immune system. Compared with vaccinated healthy-
weight adults, vaccinated obese adults have twice the risk of influenza
or influenza-like illness despite equal serological response to
vaccination. This challenges the current standard of protection for
influenza and suggests that further vaccination methods or
therapeutics are required to combat this virulent respiratory virus.
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Influenza is a highly contagious respiratory
tract infection caused by the influenza virus.
On average, approximately 12,000 to 56,000
people die as a result of influenza infection
in the United States each year (1). Globally,
influenza has a mortality burden of
approximately 250,000 to 500,000, with as
many as 3 million to 5 million individuals
severely affected by influenza each year (2).
Influenza infection occurs primarily in
cold-weather months because communal
living and dry air promote the spread of the
virus (3). Unlike other respiratory tract
infections, influenza has a very rapid onset,
characterized by a fever greater than 1008F
and a cough in the absence of other causes.
Other symptoms typically include
headache, malaise, sore throat, congestion,
body aches, and nausea or vomiting (2).
Influenza is a segmented RNA virus
encapsulated by a host lipid envelope with
two prominent viral peptides comprising its
surface: hemagglutinin and neuraminidase.
There are four strains of influenza virus—A,
B, C, and D—with influenza A and B being
the most common causes of infection in
humans (4, 5). Antigenic drift, manifesting
as small seasonal changes in hemagglutinin
or neuraminidase, induced by evolutionary
pressures from host immunity allows the
virus to escape from antibody detection
generated against the earlier influenza
strain, potentially leading to reinfection of
the same individual. Antigenic shift, or a
combination of two or more influenza
viruses to form a new influenza virus, can
result in a pandemic, in which a virus
spreads quickly throughout the population
because of lack of previous exposure to this
new influenza viral strain (4, 5).
In 1918, the “Spanish flu” pandemic
impacted nearly one-third of the world’s
population and caused approximately
50 million deaths (6). Other influenza
pandemics have occurred since 1918, often
resulting from a zoonotic transfer of
influenza from pigs or birds to humans.
However, none has caused a similar degree
of impact as the pandemic of 1918. This
extreme example serves as a public health
warning of the dramatic impact that a novel
influenza virus can have on the overall
population, highlighting the importance of
prevention of this highly virulent
respiratory tract infection.
Currently, vaccination remains the
primary means of preventing influenza
infection. Influenza vaccination typically
involves an intramuscular injection of either
trivalent or quadrivalent inactivated split
vaccine composed of influenza A and B
strains (7). Vaccination works by priming
the immune system, thereby stimulating
humoral and cellular immunological
memory, such that upon secondary
exposure, a swift and robust immune
response can clear the pathogen, thus
preventing infection and/or symptoms.
Influenza vaccination occurs yearly to
combat genetic drift in influenza, reducing
the risk of potential epidemics each season.
However, despite vaccination efforts,
several populations of individuals, such as
young children, the elderly, and the
immunocompromised, have increased risk
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of influenza infection (8–10). Paramount in
developing new therapeutics and vaccines
to combat influenza infection is developing
methods for stimulating immune
protection for these high-risk populations.
Obesity as a Novel Risk Factor
for Influenza
Obesity has long been associated with higher
risks of chronic diseases; however, recent
data highlight obesity’s association with a
greater risk of infectious diseases (11, 12).
Following the first pandemic influenza
outbreak of the 21st century, the 2009
H1N1 swine flu, obesity (body mass index
[BMI], >30.0 kg/m2) was identified as an
independent risk factor for increased
morbidity and mortality resulting from
pandemic H1N1 (pH1N1) infection (13).
Louie and colleagues identified 51% of 534
adult cases of influenza in California during
the 2009 H1N1 pandemic outbreak
occurring in obese individuals, with 61% of
influenza mortality cases happening in
obese adults (13). Additionally, compared
with healthy-weight adults, obese adults
were found to have a higher risk of
hospitalization for respiratory illness during
seasonal influenza, with 1.45 times the odds
of contracting seasonal influenza for
adults with BMIs ranging from 30.0 to
34.9 kg/m2 and 2.12 times the odds for
adults with BMIs greater than or equal to
35.0 kg/m2 (14).
This identification of obesity as a high-
risk group for influenza infection presents a
serious public health problem, given the
exponential rise in obesity over the past few
decades. Recently, for the first time in
recorded human history, obese adults were
found to outnumber underweight adults
worldwide, suggesting that increases in the
prevalence of obesity are not isolated to one
particular region but reflective of an overall
global trend (15). This alarming rise in the
prevalence of obesity, coupled with its
identification as a risk factor for influenza,
increases the threat of severe infection for
the nearly 500 million obese individuals
worldwide (16). This observation begs
several questions: How does obesity
increase the risk of influenza infection?
What mechanistic aspects of obesity cause
greater lung pathology, complications,
and/or mortality? How can data be used to
better inform measures of influenza
prevention, such as vaccination or
therapeutic intervention?
Obesity and Influenza: Key
Insights Gleaned from
Animal Models
Recent findings usingmodels of obesity have
elucidated key insights into possible
mechanisms of influenza infection in the
obese. Murine models of obesity provide a
unique translational option to study
influenza’s impact in vivo (17). Similar to
epidemiological observations in obese
adults, compared with lean mice, mice with
diet-induced obesity infected with influenza
virus have higher mortality rates (18).
Obese mice developed greater lung
inflammation and damage, higher numbers
of cytotoxic CD81 T cells, and fewer
suppressive T-regulatory cells (18, 19).
Additionally, impairments in immune
responses of obese mice occurred upon
secondary influenza infection, whereby a
primary sublethal influenza infection
stimulated immunological memory
much like vaccination. In these studies,
compared with lean mice, obese mice
infected with pH1N1 showed decreased
memory CD81 T-cell production of IFN-g,
a key cytokine involved in influenza
clearance (20).
Other studies using mice with diet-
induced obesity infected with influenza have
demonstrated decreased populations of
bone marrow–resident B cells, the primary
memory cells responsible for antibody
production (21). This lack of memory
B-cell development is further supported by
the finding that influenza-specific
antibodies were absent in obese mice at 35
days postinfection (19). Furthermore,
Karlsson and coworkers found that obese
mice had lower influenza-specific antibody
production than lean mice despite
increased production of neutralizing and
nonneutralizing influenza-specific
antibodies following adjuvant vaccination
(22). Furthermore, obese mice had higher
mortality even after adjuvant vaccine–
stimulated production of influenza-specific
antibodies, thus suggesting that obesity-
impaired cellular immune responses are
responsible for higher morbidity and
mortality resulting from influenza (22).
These models of mice with obesity
induced by a high-fat diet mimic
observations seen in clinical settings.
However, the question as to whether obesity
or diet influences the outcome of infection
remains an inherent limitation of these types
of models. In other models, researchers have
used global leptin receptor–knockout mice
(db/db) to study the effects of obesity in
response to influenza infection. Leptin, a
hormone produced by adipocytes and
responsible for regulating satiety, binds its
receptor in the hypothalamus and thus
signals a state of fullness. This type of
model eliminates diet as a potential
confounder because db/db mice become
obese when fed a standard chow diet, due
to a lack of leptin-stimulated satiety
signaling. However, global depletion of
leptin receptors also affects other cell types
that use leptin signaling.
Compared with wild-type lean mice,
leptin receptor–deficient obese mice
(db/db) displayed greater mortality, higher
measures of lung inflammation, and
decreased viral clearance when infected
with the pH1N1 influenza virus (23).
Interestingly, selectively knocking out
leptin receptors by crossing transgenic Cre
and fully floxed (fl) mice for macrophages
(LysM-Cre1/1/LepRfl/fl) and lung epithelial
cells (SP-C-Cre1/1/LepRfl/fl) of influenza-
infected lean mice did not alter viral
clearance, lung damage, or mortality
compared with wild-type mice (23).
These data suggest that leptin signaling in
other immune cell types may be critical in the
adaptive immune response to influenza virus.
Other studies support evidence suggesting
that leptin plays a critical role in the immune
response of T cells to pathogens through
promoting the glycolytic activity of effector T
cells (24).
To confirm whether obesity
independent of diet accounts for the
observed impairments in response to
influenza, our laboratory used a
hypothalamic leptin receptor–knockout
(LepRH2/2) model in mice. After crossing a
fully floxed leptin receptor mouse with a
Cre transgenic mouse under control of the
Nkx2.1 promoter [C57BL/6J-Tg(Nkx2-1-
cre)2S], mice lacking hypothalamic leptin
receptors became obese as a result of
hyperphagia while consuming the same chow
diet as their lean controls (LepRHFlox/Flox)
(18). In this model, hypothalamic leptin–
deficient obese mice (LepRH2/2),
compared with lean mice (LepRHFlox/Flox)
fed identical diets, were found to have
increased mortality following infection with
pH1N1 influenza. Additionally, obese
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LepRH2/2 mice had fewer CD41 and
CD81 T cells as well as reduced numbers
and activity of bronchoalveolar lavage
T-regulatory cells (18). Interestingly,
compared with lean controls, both mice
with diet-induced obesity and obese
LepRH2/2 mice had altered metabolic
profiles in lung tissue following pH1N1
infection (18).
Further investigations revealed that,
following influenza infection, obese mice
displayed altered metabolic profiles in lung,
liver, mesenteric white adipose tissue,
serum, urine, and feces (25). These studies
demonstrate impairments in the metabolic
profile as well as the immune response of
obese mice compared with wild-type lean
mice in response to influenza infection.
Furthermore, leptin may play a critical role
in the immune response of specific cell
types in response to influenza virus. Obesity
is inherently a metabolic condition in
which prolonged caloric intake results in
hormone and nutrient dysregulation and a
proinflammatory environment. This
altered metabolic milieu suggests that
metabolic factors may account for
higher rates of influenza infection and
mortality.
Obesity and Influenza:
Translational Insights into
Possible Mechanisms
In addition to model studies using mice,
clinical research studies with human
subjects have also yielded great insight into
how obesity alters the immune response to
influenza. In 2011, our group established an
observational clinical study in which
participants received the influenza vaccine
and underwent pre- and postvaccination
venous blood draws to isolate serum and
peripheral blood mononuclear cells. We
found that at 30 days postvaccination, there
were no significant differences in influenza-
specific serological responses to the vaccine
between healthy-weight, overweight, and
obese individuals. Interestingly, however,
overweight and obese adults had a greater
decline in influenza-specific antibody titers
at 1 year postvaccination (26).
In addition, peripheral blood
mononuclear cells from influenza-
vaccinated healthy-weight, overweight, and
obese adults were stimulated with H1N1
influenza virus in vitro. We found that
CD41 and CD81 T cells from obese and
overweight adults expressed fewer
activation and functional markers than
those from healthy-weight adults (27).
These impairments included less expression
of activation markers CD28, CD40 ligand,
CD69, and IL-12R as well as reduced
expression of IFN-g and granzyme B,
critical cytokines produced by effector T
cells involved in influenza clearance (25).
Additionally, there were no differences in
dendritic cell activation or function,
suggesting that obesity affects T-cell
activation and function independently of
antigen presentation (25).
In the 2013–2014 and 2014–2015
influenza seasons, our group examined the
influenza-specific antibody responses of
1,022 study participants monitored weekly
for laboratory confirmed influenza or
influenza-like illness. We found that,
compared with vaccinated healthy-weight
adults, vaccinated obese adults had twice
the risk of influenza or influenza-like illness
despite equivalent influenza-specific
antibody responses to the vaccine (28). This
finding suggests that impairments in the
cellular immune response, namely CD41
and CD1 effector T cells, are responsible
for the higher observed risk of obese
adults for influenza. This finding challenges
the current standard of protection for
influenza vaccination. This suggests that
obese adults may need alternative
approaches to achieve protection from
influenza, much like the elderly and
immunocompromised.
Obesity, as a metabolic condition,
often leads to hyperinsulinemia,
hyperleptinemia, and nutrient
dysregulation. Furthermore, how T-cell
metabolism drives cell homeostasis,
proliferation, and function is well
established (29, 30). Given impairments of
T cells in murine models of influenza
infection coinciding with alterations in the
metabolic milieu of obese mice, it is
plausible that alterations in the metabolic
profile of T cells stemming from obesity
may drive functional impairments. Recent
studies have demonstrated how insulin
and leptin signaling in T cells can drive
glycolytic profiles of effector T cells,
supporting cell proliferation and function
(24, 31). Other factors, such as
inflammatory cytokines and adipocyte
activation of T cells, have been implicated
in the skewing of T-cell populations, thus
promoting a proinflammatory
microenvironment and impairing the
immune response to influenza (32–34).
However, how excess insulin or leptin
signaling, along with other obesogenic
factors, alters the metabolic profile and
thus the function of these critical immune
cells remains unknown.
Conclusions
Influenza is a highly contagious respiratory
tract infection that causes seasonal impacts
each year. Furthermore, influenza poses a
significant public health threat because the
introduction of a novel virus has the
potential to create a highly pathogenic
pandemic. Recent identification of obesity as
an independent risk factor for influenza
morbidity and mortality increases the risk of
influenza infection for nearly 500 million
obese individuals worldwide.
Understanding the mechanistic role obesity
plays in increasing the risk of influenza
morbidity and mortality remains
fundamental to combating this virulent
pathogen.
Recent findings that vaccinated obese
adults have twice the risk of influenza or
influenza-like illness compared with
vaccinated healthy-weight adults despite
equal serological response to vaccine
challenge the current standard of protection
for influenza. Translational data suggest that
an alteration in the metabolic profile of T
cells in obese individuals impairs the
activation and function of these critical
adaptive immune cells. How do systemic
metabolic alterations of obesity directly
affect immune responses to influenza? We
propose that hyperinsulinemia or
hyperleptinemia may lead to the metabolic
dysregulation of T cells, thus impairing their
function in response to influenza. Hence,
metabolic restoration of cellular immune
cells may be critical to restoring their
function and reduce the risk of influenza
morbidity and mortality in obese
individuals. n
Author disclosures are available with the text
of this article at www.atsjournals.org.
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